文献速递认知障碍与谵妄衰弱、肌少症与跌倒多重用药

阿尔茨海默病患者使用抗精神病药与头部损伤风险

The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease.
PubMed 文献 · J Am Geriatr Soc · 2020-01-07

结果显示,抗精神病药使用与头部损伤(IPT加权HR=1.29,95%CI=1.14-1.47)及创伤性脑损伤(TBI;HR=1.22,95%CI=1.03-1.45)风险升高相关;喹硫平使用者TBI风险高于利培酮使用者(HR=1.60,95%CI=1.15-2.22)。

要点

  • AD患者使用抗精神病药与头部损伤及TBI住院或死亡风险升高相关。
  • 喹硫平使用者TBI风险高于利培酮使用者,需进一步研究确认。
  • 抗精神病药应限于最严重神经精神症状,参照AGS Beers标准。

核心结论

  • 抗精神病药使用可能增加AD患者头部损伤和TBI风险,应限制用于最严重神经精神症状。

主要发现

  • 抗精神病药使用者头部损伤事件率为1.65/100人年(95%CI=1.50-1.81),非使用者为1.26/100人年(95%CI=1.16-1.37),IPT加权HR=1.29(95%CI=1.14-1.47)。
  • 抗精神病药使用者TBI事件率为0.90/100人年(95%CI=0.79-1.02),非使用者为0.72/100人年(95%CI=0.65-0.81),IPT加权HR=1.22(95%CI=1.03-1.45)。
  • 喹硫平使用者TBI风险高于利培酮使用者,IPT加权HR=1.60(95%CI=1.15-2.22)。

关键数值与推荐

  • 头部损伤定义为ICD-10编码S00-S09导致住院或死亡,TBI定义为ICD-10编码S06.0-S06.9导致住院或死亡。
  • 抗精神病药使用应限于最严重神经精神症状,参照AGS Beers Criteria推荐。

临床怎么用

  • 对AD患者处方抗精神病药前应评估跌倒与头部损伤风险,并严格限定于最严重神经精神症状。
  • 选择抗精神病药时可考虑TBI风险差异,喹硫平使用者TBI风险高于利培酮使用者。

局限性

  • 喹硫平与利培酮TBI风险差异需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Antipsychotic use is associated with risk of falls among older persons, but we are not aware of previous studies investigating risk of head injuries. We studied the association of antipsychotic use and risk of head injuries among community dwellers with Alzheimer's disease (AD). DESIGN: Nationwide register-based cohort study. SETTING: Medication Use and Alzheimer's Disease (MEDALZ) cohort, Finland. PARTICIPANTS: The MEDALZ cohort includes Finnish community dwellers who received clinically verified AD diagnosis in 2005 to 2011. Incident antipsychotic users were identified from the Prescription Register and matched with nonusers by age, sex, and time since AD diagnosis (21 795 matched pairs). Persons with prior head injury or history of schizophrenia were excluded. MEASUREMENTS: Outcomes were incident head injuries (International Classification of Diseases, Tenth Revision [ICD-10] codes S00-S09) and traumatic brain injuries (TBIs; ICD-10 codes S06.0-S06.9) resulting in a hospital admission (Hospital Discharge Register) or death (Causes of Death Register). Inverse probability of treatment (IPT) weighted Cox proportional hazard models were used to assess relative risks. RESULTS: Antipsychotic use was associated with an increased risk of head injuries (event rate per 100 person-years = 1.65 [95% confidence interval {CI} = 1.50-1.81] for users and 1.26 [95% CI = 1.16-1.37] for nonusers; IPT-weighted hazard ratio [HR] = 1.29 [95% CI = 1.14-1.47]) and TBIs (event rate per 100 person-years = 0.90 [95% CI = 0.79-1.02] for users and 0.72 [95% CI = 0.65-0.81] for nonusers; IPT-weighted HR = 1.22 [95% CI = 1.03-1.45]). Quetiapine users had higher risk of TBIs (IPT-weighted HR = 1.60 [95% CI = 1.15-2.22]) in comparison to risperidone users. CONCLUSIONS: These findings imply that in addition to previously reported adverse events and effects, antipsychotic use may increase the risk of head injuries and TBIs in persons with AD. Therefore, their use should be restricted to most severe neuropsychiatric symptoms, as recommended by the AGS Beers Criteria®. Additionally, higher relative risk of TBIs in quetiapine users compared to risperidone users should be confirmed in further studies. J Am Geriatr Soc 68:595-602, 2020.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Tapiainen V, Lavikainen P, Koponen M, et al. The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease. J Am Geriatr Soc. 2020. PMID: 31912482. doi:10.1111/jgs.16275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。